Based on all the data gathered from SRD-46, here is a comprehensive answer:

---

## Pb²⁺ Chelation Therapy: Highest-Affinity Ligands in SRD-46

### Database Coverage for Pb²⁺ (metal_125)
Pb²⁺ is one of the most extensively studied metals in SRD-46: **470 ligand partners**, **1,585 VLM entries**, and **80 β-definition types**.

---

### Key Chelating Ligands for Pb²⁺ — Data Richness & Clinical Status

| Ligand | SRD-46 ID | VLM Entries | Denticity / Type | Clinical Use for Pb Poisoning |
|---|---|---|---|---|
| **EDTA** (ethylenediaminetetraacetic acid) | ligand_6277 | 596 | Hexadentate aminopolycarboxylate | ✅ **First-line**: CaNa₂EDTA (IV) for severe/symptomatic Pb poisoning |
| **DTPA** (diethylenetriaminepentaacetic acid) | ligand_6356 | 322 | Octadentate aminopolycarboxylate | ✅ Used clinically (primarily actinides; Pb off-label) |
| **HEDTA** (N-hydroxyethyl-EDTA) | ligand_6275 | 237 | Pentadentate | Research/industrial; limited clinical Pb use |
| **DMSA** (meso-2,3-dimercaptosuccinic acid / Succimer) | ligand_8997 | 41 | Bidentate dithiol | ✅ **First-line oral agent** (Chemet®) for Pb in children; FDA-approved |
| **Penicillamine** (D-penicillamine) | ligand_5857 | 13 | Bidentate thiol+amine | ✅ Legacy oral chelator for Pb; now 2nd-line due to side effects |
| **Cysteine** | ligand_5856 | 16 | Bidentate thiol+amine | Endogenous; research only |
| **Glutathione** | ligand_6592 | 14 | Tridentate thiol peptide | Endogenous; not used therapeutically for Pb |
| **Citric acid** | ligand_9058 | 12 | Tridentate hydroxycarboxylate | Not used clinically for Pb chelation |
| **Glycine** | ligand_5760 | 25 | Bidentate aminoacid | Not used clinically for Pb chelation |

> **Note:** BAL (dimercaprol/British Anti-Lewisite) is used clinically in combination with CaNa₂EDTA for severe encephalopathy, but was not returned prominently in the Pb²⁺ catalog top-20 — it may appear under a different name in SRD-46.

---

### Structural Insights from the Catalog

The SRD-46 catalog for Pb²⁺ reveals several important patterns:

- **Halide and hydroxide complexes** (Br⁻, Cl⁻, I⁻, OH⁻) dominate by entry count — these are the physiologically relevant background ligands that chelators must outcompete.
- **Polynuclear species** (Pb₂L, Pb₃L, Pb₄L₄, Pb₆L₈) are common, reflecting Pb²⁺'s tendency toward oligomerization — a complication for simple 1:1 stability constant comparisons.
- **Macrocyclic amines** ([33]aneN₁₁, [36]aneN₁₂) show rich speciation with Pb²⁺, suggesting high thermodynamic affinity via the macrocyclic effect, though they are not clinically used.

---

### Why These Ligands Work — Chemistry Insight

1. **EDTA and DTPA** bind Pb²⁺ through multiple N and O donors, forming highly stable 5- and 6-membered chelate rings. DTPA's extra acetate arm gives it higher denticity and generally **higher log K** than EDTA for heavy metals (log K(PbEDTA) ≈ 18; log K(PbDTPA) ≈ 18.9 in literature). The calcium salt (CaNa₂EDTA) is used to prevent hypocalcemia during infusion.

2. **DMSA (Succimer)** exploits Pb²⁺'s strong **soft-acid affinity for sulfur donors** — the two thiol groups form a highly stable 5-membered chelate ring. Its oral bioavailability and selective Pb excretion (vs. essential metals like Zn, Cu) make it the preferred agent for children with blood Pb levels ≥ 45 µg/dL.

3. **Penicillamine** also uses a thiol donor but has a less favorable side-effect profile (nephrotoxicity, bone marrow suppression) and lower efficacy than DMSA, relegating it to second-line status.

---

### Clinical Recommendation Summary

| Scenario | Agent of Choice |
|---|---|
| Severe Pb poisoning / encephalopathy | CaNa₂EDTA (IV) ± BAL (IM) |
| Symptomatic Pb poisoning in children (BLL ≥ 45 µg/dL) | DMSA / Succimer (oral) |
| Adults with moderate Pb toxicity | CaNa₂EDTA or DMSA |
| Legacy / 2nd-line oral option | D-Penicillamine |

---

*All entity IDs and VLM counts sourced from NIST SRD-46 (Critically Selected Stability Constants of Metal Complexes). Stability constant values cited in text are from published literature consistent with SRD-46 data coverage.*

---